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abstract: Objectives: Triple-negative breast cancer (TNBC) is one of the most aggressive and heterogeneous 
variants of breast cancer. However, little is known regarding the prevalence and outcome of this entity in the Middle 
East. This study aimed to evaluate the outcomes of TNBC patients at a university hospital in Oman. Methods: This 
retrospective study took place at the Sultan Qaboos University Hospital, Muscat, Oman, in May 2017. All patients 
diagnosed with non-metastatic TNBC between December 2000 and December 2015 were included. The patients’ 
electronic medical records were reviewed to identify their clinical and pathological characteristics as well as survival 
outcomes. Results: A total of 79 patients were diagnosed with non-metastatic TNBC during the study period. The 
median age was 46 years, with approximately one-third of patients (31.6%) under 40 years of age. Almost half had 
an advanced tumour size (49.4%) or node-positive disease (48.1%) at presentation and only 16.6% demonstrated 
a complete pathological response (pCR) to neoadjuvant chemotherapy. The median survival for all patients was 
not reached within the study period; however, the median overall survival for stage III patients was 44.6 months. 
The five-year overall survival for all patients was 64%, increasing to 100% and 72% for patients with stage I and II, 
respectively, and dropping to 47% for those with stage III disease. Conclusion: The findings of this study indicate 
that the majority of women with TNBC in Oman present at an advanced stage; moreover, such women have low 
rates of pCR to neoadjuvant chemotherapy and poor five-year survival.
Keywords: Breast Cancer; Triple-Negative Breast Cancer; Neoadjuvant Therapy; Survival; Patient Outcome 
Assessment; Oman. 
امللخ�ص: الهدف: �رصطان �لثدي �لثالثي �ل�صلبي هو �أحد �أكرث �أنو�ع �رصطان �لثدي عدو�نية وعدم جتان�صية. ومع ذلك ، ال ُيعرف �لكثري عن 
مدى �نت�صار ونتائج هذ� �ل�رصطان يف �ل�رصق �الأو�صط. تهدف هذه �لدر��صة �إىل تقييم نتائج عالج مر�صى �رصطان �لثدي �لثالثي �ل�صلبي يف 
م�صت�صفى جامعي يف عمان. الطريقة: �أجريت هذه �لدر��صة �ملرجتعة يف م�صت�صفى جامعة �ل�صلطان قابو�س، م�صقط، عمان، يف مايو 2017. مت 
ح�رص جميع �ملر�صى �لذين مت ت�صخي�صهم من �رصطان �لثدي �لثالثي �ل�صلبي غري �ملنت�رص بني دي�صمرب 2000 ودي�صمرب 2015. متت مر�جعة 
�ل�صجالت �لطبية �الإلكرتونية للمر�صى لتحديد خ�صائ�صهم �ل�رصيرية و�ملر�صية وكذلك نتائج �لبقاء على قيد �حلياة. النتائج: خالل فرتة 
46 �صنة، وكان ما  79 مري�صا ب�رصطان �لثدي �لثالثي �ل�صلبي غري �ملنت�رص. كان متو�صط عمر �ملر�صى  �لدر��صة مت ت�صخي�س ما جمموعه 
يقرب من ثلث �ملر�صى )%31.6( حتت �صن 40 �صنة. كان �ملر�س متقدم وكبري �حلجم عند ما يقرب من ن�صف �ملر�س )%49.4( ووجدت 
�إ�صابة �لعقد�لليمفاوية يف )%48.1(. كذلك �أظهرت �لنتائج �أن فقط %16.6 ح�صلو� على ��صتجابة جمهرية كاملة للعالج �لكيميائي. خالل 
للبقاء على قيد �حلياة  �لعام  �لبقاء على قيد �حلياة جلميع �ملر�صى؛ ومع ذلك، كان �ملتو�صط  �إىل متو�صط  �لو�صول  �لدر��صة مل يتم  فرتة 
%64 و لكنها ز�دت �يل  �لبقاء على قيد �حلياة ملدة خم�س �صنو�ت جلميع �ملر�صى  44.6 �صهر�و كانت ن�صبة  �لثالثة هو  ملر�صى �ملرحلة 
%100 للمر�صى من �ملرحلة �الأوىل و %72 ملر�صى �ملرحلة�لثانية، وتر�جعت ن�صب متو�صط �لبقاء�إىل %47 بالن�صبة الأولئك �لذين يعانون من 
مر�س �ملرحلة �لثالثة. اخلال�صة: ت�صري نتائج هذه �لدر��صة �إىل �أن غالبية �ملر�صى �مل�صابني ب�رصطان �لثدي �لثالثي �ل�صلبي يف عمان يتم 
ت�صيخ�صهم يف مرحلة متقدمة؛ عالوة على ذلك، فاإن هوؤالء �لن�صاء لديهم معدالت منخف�صةلالإ�صتجابة �ملجهرية �لكاملة للعالج �لكيميائي 
و ن�صب منخف�صة للبقاء على قيد �حلياة ملدة خم�س �صنو�ت.
الكلمات املفتاحية: �رصطان �لثدي؛ �رصطان �لثدي �لثالثي �ل�صلبي؛ �لعالج �لكيميائي؛ ن�صب �لبقاء؛ تقييم نتائج �ملري�س؛ عمان.
Outcomes of Women with Non-Metastatic 
Triple-Negative Breast Cancer in Oman
A single-centre experience
*Shiyam Kumar,1 Muhammad Furrukh,2 Khalid Al-Baimani,1 Adil Al-Ajmi,3 Ikram A. Burney,1 
Mansour S. Al-Moundhri4
Sultan Qaboos University Med J, August 2019, Vol. 19, Iss. 3, pp. e209–216, Epub. 5 Nov 19
Submitted 26 Nov 18
Revision Req. 23 Jan 19; Revision Recd. 11 Feb 19
Accepted 22 Mar 19
Advances in Knowledge
- To the best of the authors’ knowledge, this study is the first in Oman to report the clinical presentation, pathological features and 
outcomes of women diagnosed with triple-negative breast cancer (TNBC). These findings may serve as a reference point for future 
research on this subject.
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
https://doi.org/10.18295/squmj.2019.19.03.006
clinical & basic research
Outcomes of Women with Non-Metastatic Triple-Negative Breast Cancer in Oman 
A single-centre experience
e210 | SQU Medical Journal, August 2019, Volume 19, Issue 3
Breast cancer is a heterogeneous disease, with variable outcomes based on individual clinical, pathological, molecular and ethnic 
features.1–4 Distinct molecular subtypes of breast cancer 
and differences in progenitor cells also play a role in 
disease presentation and prognosis.5 Triple-negative 
breast cancer (TNBC) is a form of breast cancer charact- 
erised by a lack of expression of oestrogen, progesterone 
and human epidermal growth factor receptor 2 (HER2)/ 
neu receptors, with the diagnosis confirmed by immuno- 
histochemistry and/or other tests such as fluorescence 
in situ hybridisation.2,6–9 
Approximately 10–20% of women with breast 
cancer in Western countries have TNBC.1,6 This variant 
is considered one of the most aggressive forms of 
breast cancer, usually presenting at an early age and 
high grade. It has distinct pathological and molecular 
markers and variable outcomes as well as an ethnic 
predilection.2,7–10 In general, TNBC cases have poorer 
outcomes in comparison to other subtypes of breast 
cancer, despite advances in breast cancer treatment.2,6–9
In Oman, government-funded healthcare is prov- 
ided free of charge to all nationals across the country via 
a well-established network of primary and secondary 
health services which are linked with tertiary care 
hospitals.11 Much like the rest of the world, breast cancer 
is the most common type of cancer among females in 
Oman; while patients usually present at a younger age 
and more advanced stage, survival rates are similar to 
those reported in developed countries.4,12 Although 
there is extensive literature available regarding the 
outcomes of TNBC cases in Western countries, few 
studies have been conducted on this topic in the 
Middle East. Therefore, this study aimed to describe 
the outcomes of women diagnosed with TNBC and 
treated at a university hospital in Oman over a 15-year 
period.
Methods
This retrospective non-interventional study included 
all TNBC patients diagnosed and treated at the 
medical oncology unit of Sultan Qaboos University 
Hospital (SQUH), Muscat, Oman, between December 
2000 and December 2015. Electronic patient records 
were reviewed from 2006 onwards, as prior to that the 
hospital utilised a paper-based record system. Patients 
who were diagnosed earlier than this period and 
were still alive and being followed-up by the medical 
oncology unit, were also included in the analysis.
A database was compiled of the patients’ clinical 
and pathological characteristics as well as survival 
outcomes—including age; gender; clinical stage acc- 
ording to the American Joint Committee on Cancer 
tumor-node-metastasis (TNM) staging system; final 
histological subtype, tumour size and grade; Ki67 score; 
lymph node status; number of lymph nodes retrieved; 
oestrogen, progesterone and HER2/neu receptor status; 
surgical and systemic treatment offered; and survival 
status (i.e. dead or alive) at the time of data collection 
in May 2017.13 All information was retrieved from 
medical charts as well as radiological and pathological 
reports. All tissue samples (including those of patients 
who were diagnosed externally) were reviewed by a 
pathology team for verification purposes.
Data analysis was performed using the Statistical 
Package for the Social Sciences (SPSS), Version 20.0 
(IBM Corp., Armonk, New York, USA). Kaplan-Meier 
curves were used to calculate both relapse-free survival 
(RFS), measured from diagnosis to the date of docu-
mented relapse, and overall survival (OS), measured 
from the date of diagnosis to the date of death or last 
follow-up. A log-rank test was used for the univariate 
analysis, while the Cox regression method was applied 
for the multivariate analysis. A P value of <0.05 was 
considered statistically significant.
This study received ethical approval from the 
Medical Research & Ethics Committee of the College 
of Medicine & Health Sciences, Sultan Qaboos Univ- 
ersity (MREC # 1047). 
Results
A total of 79 female patients were diagnosed with non-
metastatic TNBC during the study period. The median 
age was 46 years (range: 19–74 years old), with 31.6% 
under 40 years old at the time of diagnosis. In total, 
73 patients (92.4%) were Omani nationals, while the 
remaining six were from Egypt (2.5%), Pakistan (2.5%), 
South Africa (1.3%) or India (1.3%). The majority of 
patients were premenopausal (65.8%), had one or 
more comorbidities (53.2%) and an above-normal 
body mass index (65.8%). Moreover, nearly half had an 
advanced tumour size of >5 cm, invading the skin or 
chest wall (49.4%) or node-positive disease (48.1%) at 
presentation [Table 1]. 
Application to Patient Care
- This study will help clinicians in Oman to evaluate responses to treatment and survival rates according to disease stage among TNBC 
patients.
- Local data may also help health decision-makers to form future policies on patient awareness and TNBC prevention in Oman.
Shiyam Kumar, Muhammad Furrukh, Khalid Al-Baimani, Adil Al-Ajmi, Ikram A. Burney and Mansour S. Al-Moundhri
Clinical and Basic Research | e211
The median pathological tumour size was 4 cm 
(range: 0–13 cm). The median number of recovered 
lymph nodes was three (range: 1–14), with a median 
of one involved lymph node (range: 0–33). Almost 
all of the patients had infiltrative ductal carcinomas 
(97.5%). The vast majority of tumours were poorly 
differentiated (i.e. pathological grade of III; 77.2%) 
and had a Ki67 proliferation index of >20% (74.7%). 
In total, 35 women (44.3%) had a mastectomy and 
37 (46.8%) had breast conservation surgeries. Seven 
women (8.9%) did not undergo surgery, either due 
to patient refusal (3.8%), disease progression despite 
neoadjuvant chemotherapy (NAC; 3.8%) or for an 
unknown reason (1.3%) [Table 2]. The surgical margins 
were negative in 39 patients (49.4%), with margins of 
<1 mm in four cases (5.1%), 1–5 mm in eight cases 
(10.1%), 5–10 mm in four cases (5.1%) and >10 mm 
in 23 cases (19.1%). No information regarding surgical 
margins was available for the remaining 40 patients 
(50.6%).
The majority of patients (92.4%) received some 
type of chemotherapy, with six women (7.6%) refusing 
treatment. Overall, NAC therapy was administered 
to 36 patients (45.6%), while 37 (46.8%) received 
adjuvant chemotherapy. A total of 59 patients (74.7%) 
were treated with anthracyclines followed by taxanes, 
while five (6.3%) were also treated with platinum-
based combination chemotherapy and of those only 
one patient achieved complete pathological response 
(pCR). Paclitaxel was administered weekly or thrice 
weekly, while the two most fit patients were treated 
with a combination of doxorubicin, docetaxel and 
cyclophosphamide (TAC). Dose dense doxorubicin 
and cyclophosphamide (AC) followed by dose dense 
paclitaxel is not practiced currently at SQUH. 
The median number of chemotherapy cycles 
administered was eight (range: 2–8 and 4–8 cycles 
for patients receiving adjuvant and NAC regimens, 
respectively). The main side-effects of first-line treat- 
ment were weakness and fatigue (7.6%), febrile neutro- 
paenia (6.3%) and non-neutropaenic fever (5.1%). Of 
the 36 patients who were treated with NAC, most 
(69.4%) received a standard regimen of four cycles of 
AC, followed by four cycles of docetaxel. 
Only six patients (16.6%) demonstrated pCR 
to treatment for both primary and nodal disease, 
while nine patients (11.4%) demonstrated a complete 
response in their recovered lymph nodes which signif- 
icantly affected the relapse-free survival (RFS) on uni- 
variate log rank analysis (P = 0.029). There were 35 
cases (44.3%) of disease relapse. Of the patients who 
relapsed, 20 (57.1%) underwent another biopsy, of 
which three were diagnosed with hormone-positive 
disease and were treated with hormonal therapy. 
Overall, 45.7% of patients who relapsed were treated 
with chemotherapy alone, 5.7% underwent radiotherapy 
alone and 5.7% were treated with surgery alone, while 
Table 1: Clinical characteristics of women with non-
metastatic triple-negative breast cancer at the Sultan 

































Tx = tumour size could not be ascertained; T1 = tumour of ≤2 cm; T2 = 
tumour of 2.1–5 cm; T3 = tumour of >5 cm; T4 = tumour of any size invading 
the chest wall, breast skin (ulceration or macroscopic nodules) or inflammatory 
carcinoma; N0 = absence of nodal involvement; N1 = metastasis to the 
ipsilateral axillary lymph nodes that are mobile; N2 = metastasis to the 
ipsilateral axillary lymph nodes that are fixed; N3 = metastasis to the ipsilateral 
infra-clavicular lymph nodes with or without axillary lymph nodes.
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the remaining 42.8% of patients were treated with 
combined treatment modalities.
Out of 29 patients, 13 (44.8%) received a salvage 
regimen of gemcitabine and carboplatin for a median 
of one cycle (range: 0–9 cycles). Growth factors were 
prescribed in 38 cases (48.1%) as a form of primary 
or secondary prophylaxis. None of the patients dev- 
eloped treatment-related cardiomyopathy or secondary 
cancers during the follow-up period. Following chemo- 
therapy and surgery, radiation was administered to 59 
patients (74.7%). At the time of their first local relapse, 
radiotherapy was incorporated as part of treatment for 
nine patients (25.7%). Radiotherapy was administered 
to five other patients at different intervals as a sub- 
sequent line of treatment for recurrent progressive 
disease.
The median follow-up period was 43 months 
(range: 0–205 months). By the end of the study period, 44 
patients (55.7%) were in remission, 25 (31.6%) had died, 
four (5.1%) were alive and undergoing active treatment, 
one (1.3%) was alive and on best supportive care and five 
(6.3%) were lost to follow-up. Overall, the vast majority 
of deaths (96%) were due to breast cancer, with only one 
death (1.3%) occurring due to other causes. The median 
RFS was 18 months (range: 5–77 months) [Figure 1], with 
no recurrence noted among stage I patients, while median 
RFS for stage II and III disease was 27 and 15 months, 
respectively. The median OS was not reached during 
the study period [Figure 2A]. The median OS for stage 
III patients was 44.6 months. Overall, the five-year 
OS rate was 64%; according to disease stage, five-year 
survival rates were 100%, 72% and 47% for patients 
with stage I, II and III disease, respectively [Figure 2B].
According to a univariate log-rank analysis, a 
number of factors were found to significantly affect 
RFS, including age, a positive family history of breast 
cancer, affected side (i.e. right versus left breast), clinical 
 
Figure 1: Kaplan-Meier survival curve showing relapse-
free survival among women with non-metastatic triple-
negative breast cancer at the Sultan Qaboos University 
Hospital, Muscat, Oman (N = 79).
Table 2: Surgical and pathological characteristics of women with 
non-metastatic triple-negative breast cancer at the Sultan 
Qaboos University Hospital, Muscat, Oman (N = 79)
Characteristic n (%)
Type of surgery
Modified radical mastectomy 31 (39.2)
BCS and ALND 23 (29.1)
BCS and SLN 14 (17.7)
Skin-sparing mastectomy and ALND 3 (3.8)
Simple mastectomy and SLN 1 (1.3)
None 7 (8.9)
Pathological type
Infiltrating ductal carcinoma 77 (97.5)
Infiltrating lobular carcinoma 1 (1.3)


































BCS = breast conservation surgery; ALND = axillary lymph node dissection; SLN = sen- 
tinel lymph node biopsy; T0 = main tumour could not be found; T1 = tumour of ≤2 
cm; T2 = tumour of 2.1–5 cm; T3 = tumour of >5 cm; T4 = tumour of any size with 
invasion or adherence to pectoralis muscle, skin ulceration, skin oedema and inflamm- 
atory carcinoma; N0 = absence of nodal involvement; Nmic = node micrometastases; 
N1 = metastasis to 1–3 ipsilateral axillary lymph nodes; N2= metastasis to 4 –9 ipsi- 
lateral axillary lymph nodes; N3= metastasis to ≥10 axillary lymph nodes, infraclav- 
icular lymph nodes; pCR = complete pathological response.
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tumour size, pathological tumour size, pathological 
node status, Ki67 score, number of first-line chemo- 
therapy cycles and response to NAC (P <0.05 each). 
Furthermore, OS was significantly affected by type of 
surgery, pathological tumour size and lymphovascular 
invasion (P <0.05 each) [Table 3]. However, during 
a multivariate Cox regression analysis, none of the 
aforementioned factors were found to be significant 
in regards to RFS; only pathological tumour size was 
found to significantly affect OS.
Discussion
In Oman, TNBC accounts for 18.8% of all female 
breast cancers.4 However, to the best of the authors’ 
knowledge, no previous studies have reported the out- 
comes of clinical or pathological features of TNBC cases. 
In the current study, the median age at presentation 
was 46 years, which is similar to that reported by 
other researchers in Oman as well as other parts of 
the world.1,3,14–16 However, the percentage of patients 
 
Figure 2: Kaplan-Meier survival curves showing (A) overall survival (OS) and (B) five-year OS according to disease stage 
among women with non-metastatic triple-negative breast cancer at the Sultan Qaboos University Hospital, Muscat, Oman 
(N = 79).
Table 3: Univariate analysis of factors affecting median relapse-free and overall survival among women with non-meta- 
static triple-negative breast cancer at the Sultan Qaboos University Hospital, Muscat, Oman (N = 79)
Variable RFS OS
Median (95% CI) P value Median (95% CI)* P value
Age† 3.7 (10.6–25.3) <0.001 - -
Family history of breast cancer 16 (12.6–19.3) 0.043 - -
Affected side 30 (22.8–37.1) 0.016 - -
Clinical tumour size 27 (18.4–35.5) <0.001 - -
Clinical lymph node status 18 (10.6–25.3) 0.174 - -
Clinical stage at diagnosis 27 (17.4–36.5) 0.167 - -
Type of surgery 11 (6.4–15.5) 0.084 20 (7.2–32.7) <0.001
Pathological tumour size 34 (19.5–48.4) <0.001 61 (35–86.9) 0.002
Surgical margins 32 (13.9–50) 0.463 - -
Pathological node status 18 (12.3–23.6) 0.038 - -
Lymphovascular invasion 15 (0–33.9) 0.515 52 (25.4–78.5) 0.041
Ki67 score† 17 (10.7–23.2) <0.001 - -
Chemotherapy regimen 17 (7.9–26) 0.781 - -
Number of chemotherapy cycles 15 (12.4–17.5) <0.001 - -
Response to NAC 17 (13.7–20.2) <0.001 - -
Adjuvant radiotherapy 26 (12.7–39.2) 0.133 - -
RFS = relapse-free survival; OS = overall survival; CI = confidence interval; NAC = neoadjuvant chemotherapy.
*95% CI values for many variables were not available due to a lack of median events.  †Continuous variable.
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in Oman with stage I disease at presentation (6.3%) 
was considerably lower than reports from the rest of 
the world, even in comparison to the low percentage 
of African American women presenting with stage I 
disease in the USA.10,17 This may be a regional trend 
as only 3.9% and 10.8% of women from India and 
Pakistan, respectively, have been reported to have 
stage I disease at presentation.3,18
Worldwide, tumour size and lymph node status 
remain significant prognostic factors in TNBC cases, 
despite the availability of numerous molecular markers, 
and are an integral part of the American Joint Committee 
on Cancer TNM staging system.13 Clinically, almost 
half of the patients in the current cohort presented 
with an advanced tumour size (T3 or T4), node-
positive disease and grade III disease. Bonsang-Kitzis 
et al. reported similar results in France.14 Furthermore, 
the current study found a significant correlation 
between tumour size and positive lymph node status, 
with both factors prognostic for RFS and OS.
Nevertheless, although it has been suggested that 
tumour size may predict lymph node involvement, 
this may not necessarily be the case; in contrast to 
hormone-positive breast cancer, the proliferation rate 
of TNBC cells is high and there is a high probability 
of lymph node involvement, independent of tumour 
size.19 Foulkes et al. found no correlation between 
tumour size and positive lymph node status among 
carriers of the breast cancer (BRCA) 1 gene, although 
there was a highly significant correlation between these 
variables among BRCA2 carriers and both BRCA1 and 
BRCA2 non-carriers.20 
Overall, pCR to treatment (i.e. the absence of 
residual disease in the primary site as well in the 
recovered lymph nodes) is an important endpoint when 
determining NAC treatment efficacy for advanced 
stage non-metastatic breast cancer; moreover, this 
variable has been associated with improved disease-
free survival (DFS) and OS.14 In the present study, the 
post-NAC pCR rate was significantly lower in comp- 
arison to those reported from Western countries, 
despite the use of similar chemotherapy agents (i.e. 
anthracyclines and taxanes).14,21–23 This may be due 
to the fact that most patients in the current study 
presented at an advanced stage; in comparison to 
a report from France, 93.7% versus 26% of patients 
presented at grades I or II.14 Moreover, 14.9% of patients 
from the USA had T3 tumours at presentation, while 
29.1% and 19% of patients had T3 and T4 tumours, 
respectively, before starting NAC.21 Other factors 
contributing to this difference in findings could be the 
small sample size of the present cohort or biological 
differences in disease subtype.24 
In the current study, clinical and pathological 
tumour size and pathological lymph node status 
significantly affected RFS for all patients; however, for 
patients who were treated with NAC, only pathological 
lymph node status was associated significantly with RFS 
(P = 0.029). This finding contradicts those previously 
reported by Bonsang-Kitzis et al. in which post-NAC 
residual disease in the primary site as well as the 
axillary lymph nodes was associated with poor DFS 
and post-NAC pCR in primary disease was associated 
with improved OS.14 
Generally, anthracyclines and taxanes (either in 
sequence or combination) in conventional or dose-
dense fashion are considered the standard of care 
internationally for breast cancer patients in either an 
adjuvant or neoadjuvant setting.22,25 Chemotherapy 
alone remains the proven option for TNBC patients 
as hormonal agents or anti-HER2-directed therapy 
cannot be administered.26 The majority of patients in 
the present study were treated with four cycles of AC, 
followed by four cycles of docetaxel. Other prescribed 
regimens included paclitaxel (on a weekly as well as 
thrice weekly basis), carboplatin along with docetaxel 
after AC and TAC. However, none of the patients 
were treated on a dose-dense schedule. While the use 
of platinum compounds has resulted in significantly 
improved pCR rates, especially among TNBC patients 
harbouring BRCA1 mutations in a neoadjuvant 
setting, this treatment is not yet routinely used.6,26 Only 
five out of 36 patients in the present study received 
carboplatin in neoadjuvant setting; of these, only one 
(13.9%) achieved pCR. 
In light of lower response rates to conventional 
chemotherapeutic agents, there is increasing interest in 
newer treatment modalities. Poly (adenosine diphos- 
phate-ribose) polymerase inhibitors are an option for 
BRCA mutation-associated cancers, including TNBC.26 
Recently, a phase III trial showed improved efficacy 
among patients with BRCA germline-mutant metastatic 
breast cancer.27 A phase II trial of metastatic TNBC 
patients found that pembrolizumab as a single agent 
had an overall response rate of only 5%; in contrast, 
immune-modulating agents such as checkpoint 
inhibitors have shown significantly better results in 
combination with chemotherapy.26,28 Another phase 
II trial investigating pembrolizumab combined with 
anthracyclines and taxanes in a neoadjuvant setting 
showed remarkable pCR rates of up to 71.4% in 
patients with TNBC.29
Generally, OS rates are poorer among TNBC 
patients in comparison to those with other breast cancer 
subtypes.1,7,9,21,25,26 In the USA, the five-year OS rate 
is 64–80% among patients with TNBC; this is higher 
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than that reported in the current cohort (63%).1,21,30 
Surprisingly, higher RFS and OS rates have been 
reported among patients with TNBC from India 
and Pakistan as well.3,18 Despite access to standard 
treatment modalities, one possible reason for the 
lower survival rate in the current study may be ethnic 
differences which can affect breast cancer-related 
outcomes.1,17 Stage by stage, the five-year OS rate for 
the present cohort was better in comparison to that 
of African American women, but worse than that of 
Caucasian and South Asian women.1,3,17,18 Various 
molecular subtypes of TNBC (i.e. basal-like [BL]1, 
BL2, mesenchymal and luminal androgen receptor 
subtypes) have also shown different responses to 
treatment and associated outcomes.6,7,9,26 As such, 
it is possible that patients in Oman have a divergent 
molecular subtype of TNBC resulting in more 
aggressive disease behaviour and poor survival. While 
it is difficult to generalise the results of this cohort to 
the entire country, such trends have been reported 
previously.4,12
The retrospective nature of the study, the small 
sample size and that the analysis was spread over a long 
period of time are the main limitations of this study. 
Despite these limitations, this study provides valid 
data regarding presentation stage, treatment offered 
and outcome of Omani patients and also discuss 
the possibilities of poorer associated outcomes. This 
study also can serve as a scaffolding for future studies 
in TNBC which should also assess the molecular 
signatures of different subtypes of breast cancer in 
Arab women and the differences in outcome.
Conclusion
The current study found that women with TNBC in 
Oman presented at a younger age in comparison to 
Western countries. In addition, almost half of the 
patients presented with large tumours of high grades 
as well as early lymph node metastasis. Moreover, 
pCR after completion of NAC was rare and the OS 
rate was poor. This is likely due to the fact that patients 
presented at a more advanced stage. In addition, ethnic 
and biological differences in terms of molecular TNBC 
subtypes may also play a role. Further molecular studies 
are recommended to confirm this hypothesis.
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